Volume 6.42 | Nov 6

Prostate Cell News 6.42 November 6, 2015
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   PCN on Twitter
Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling
Investigators evaluated a tumor suppressive function of flightless I (FLII) in regulating AR in prostate cancer progression. Prostate cancer cells stably expressing FLII or shRNA knockdown were used for functional analyses. [Clin Cancer Res] Abstract
Learn More: Standardized Tools for Cancer Research
PUBLICATIONS (Ranked by impact factor of the journal)

Cadherin-11 Endocytosis through Binding to Clathrin Promotes Cadherin-11-Mediated Migration in Prostate Cancer Cells
Scientists examined whether cadherin-11 (Cad11) endocytosis plays a role in Cad11-mediated migration. Using GST pulldown assay, they found that clathrin binds to Cad11 but not E-cadherin cytoplasmic domain. [J Cell Sci] Abstract

Complex-I Alteration and Enhanced Mitochondrial Fusion Are Associated with Prostate Cancer Progression
The impact of mtDNA depletion on mitochondria (mt) integrity, presence of mtDNA and protein in sera exosomes was determined. A co-culture of human prostate cancer cells and the circulating exosomes followed by confocal imaging determined co-localization of exosomes and mt. [J Cell Physiol] Abstract

miR-449a Enhances Radiosensitivity through Modulating pRb/E2F1 in Prostate Cancer Cells
Researchers report that miR-449a enhances radiation-induced G2/M phase arrest and apoptosis through modulating pRb/E2F1 and sensitizes prostate cancer cells to X-ray radiation. [Tumor Biol] Abstract

Octreotide in Combination with AT-101 Induces Cytotoxicity and Apoptosis through Up-Regulation of Somatostatin Receptors 2 and 5 in DU-145 Prostate Cancer Cells
The possible synergistic cytotoxic and apoptotic effect of octreotide in combination with AT-101 was investigated in DU-145 hormone and drug refractory prostate cancer cell line. [Tumor Biol] Abstract

3-Bromopyruvate Induces Rapid Human Prostate Cancer Cell Death by Affecting Cell Energy Metabolism, GSH Pool and the Glyoxalase System
The authors tested 3-bromopyruvate (3-BP) on human prostate cancer cells showing, differently from other tumor types, efficient ATP production and functional mitochondrial metabolism. They found that 3-BP rapidly induced cultured androgen-insensitive and androgen-responsive prostate cancer cell death at low concentrations with a multimodal mechanism of action. [J Bioenerg Biomembr] Abstract

Gypensapogenin H, a Novel Dammarane-Type Triterpene Induces Cell Cycle Arrest and Apoptosis on Prostate Cancer Cells
Researchers report the effects of gypensapogenin H on human prostate cancer cells. It significantly inhibited proliferation, decreased survival, led to G1 cell cycle arrest and induced apoptosis in both cell lines, while having lesser effect on the growth of normal human gastric mucosa cells, embryonic kidney cells and lung fibroblast cells. [Steroids] Abstract

Overexpression of Lysine-Specific Demethylase 1 Promotes Androgen-Independent Transition of Human Prostate Cancer LNCaP Cells through Activation of the AR Signaling Pathway and Suppression of the p53 Signaling Pathway
Scientists investigated the correlation of lysine-specific demethylase 1 (LSD1) expression with androgen-independent (AI) transition of human androgen-dependent prostate cancer (PCa) LNCaP cells. They showed that LSD1 was overexpressed in human PCa specimens and in AI PCa LNCaP-AI cells, which were established through a three-month continuous culture of LNCaP cells in androgen-deprived medium. [Oncol Rep] Abstract

Autophagy Inhibition Enhances Silibinin-Induced Apoptosis by Regulating Reactive Oxygen Species Production in Human Prostate Cancer PC-3 Cells
The authors showed that silibinin triggered autophagy through up-regulation of microtubule-associated protein 1 light chain 3-II, formation of acidic vesicular organelles and punctuate of GFP-LC3, which was inhibited by 3-methyladenine, an inhibitor of specific autophagy. [Biochem Biophys Res Commun] Abstract


Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer
Open-label Phase I and II studies evaluated the efficacy and safety of galeterone in patients with treatment-naive nonmetastatic or metastatic castration-resistant prostate cancer and established a dose for further study. [Clin Cancer Res] Abstract

Toremifene, a Selective Estrogen Receptor Modulator, Significantly Improved Biochemical Recurrence in Bone Metastatic Prostate Cancer: A Randomized Controlled Phase II a Trial
Toremifene with conventional androgen-deprivation therapy significantly improved the biochemical recurrence rate in treatment-naïve bone metastatic prostate cancer. [BMC Cancer] Full Article

FREE ALDEFLUOR™ Protocol Optimization Resource Pack – Get Yours
Notch Signaling in Prostate Cancer: Refining a Therapeutic Opportunity
Many published studies have documented consistent deregulation of major Notch signaling components in human prostate cancer cell lines, mouse models for prostate cancers, and human prostate cancer specimens at both the mRNA and the protein levels. However, functional studies in human cancer cells by modulation of Notch pathway elements suggest both tumor suppressive and oncogenic roles of Notch. [Histol Histopathol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment
GSK and Merck announced the initiation of a Phase I clinical trial designed to evaluate GSK’s investigational immunotherapy GSK3174998 as monotherapy and in combination with Merck’s anti-PD-1 therapy, Keytruda® in patients with locally advanced, recurrent or metastatic solid tumor(s) that have progressed after standard treatment. [GlaxoSmithKline plc] Press Release

TSRI Team Wins $1.8 Million to Study Early Events in Cancer Metastasis
Scientists at The Scripps Research Institute (TSRI) have been awarded a grant of more than $1.8 million from the National Institutes of Health’s National Cancer Institute to investigate the molecular machinery involved in metastasis. [The Scripps Research Institute] Press Release

From our sponsor: Culturing hematopoietic stem and progenitor cells? Download the technical bulletin.
Canada Creates Science-Minister Post
Canada’s new prime minister, Justin Trudeau, created the post of Minister of Science as one of his first acts. Kirsty Duncan, a medical geographer at the University of Toronto, will be the first to hold the job. [Nature News] Editorial

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Cell Culture 2016
February 2-4, 2016
London, United Kingdom

Visit our events page to see a complete list of events in the prostate cell community.
NEW Postdoctoral Researcher – Computational Modelling of Prostate Cancer (IBM, Zurich Research Laboratory)

Postdoctoral Position – Androgen Response in Prostate Cancer (University of Victoria)

Computational Biologist – Prostate Cancer (Cancer Research UK Manchester Institute)

Group Leader Position – Cancer Research (Oslo University Hospital)

Division Head – Medical Oncology (Fred Hutchinson Cancer Research Center)

Postdoctoral Position – Epigenetics and Cancer (Moffitt Cancer Center)

Postdoctoral Position – Cancer Research (University of Texas Health Science Center at Houston)

PhD Studentships – Cancer Research (Cancer Research UK Manchester Institute)

Postdoctoral Associate – Bioinformatics (Baylor College of Medicine)

Postdoctoral Fellow – Prostate Cancer Research (Rutgers Cancer Institute of New Jersey)

Postdoctoral Positions – Stem Cell, Development and Cancer Biology (Columbia University Medical Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us